Charles Bryan, MD
Hematology & Oncology · Asheville, NCNPI 1831189877
Payments from drug & device makers
Across 77 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$329
- Novartis$317
- Jazz Pharmaceuticals Inc.$150
- Pfizer$143
- Merck$89
- Amgen$83
- plus $684 from 24 others
What the payments were for
- Food & beverage$1,64492%
- Education$1518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 14 | $329 |
| Novartis | 12 | $317 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Pfizer | 7 | $143 |
| Merck | 4 | $89 |
| Amgen | 5 | $83 |
| Bristol Myers Squibb | 4 | $75 |
| Beigene USA, Inc. | 3 | $68 |
| AstraZeneca | 2 | $49 |
| AbbVie | 2 | $45 |
| Gilead | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Exelixis Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Bayer | 1 | $27 |
| Array Biopharma Inc | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $23 |
| Genmab U.S., Inc. | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Morphosys, US Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Syndax Pharmaceuticals, Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Coherus Oncology, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPZELCA$150
How this compares
$1,795 in reported general payments places this provider in the 35th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 66 | $1,043,541 |
| TagrissoOsimertinib Mesylate | 23 | $348,323 |
| XtandiEnzalutamide | 37 | $341,751 |
| IbrancePalbociclib | 20 | $308,301 |
| JakafiRuxolitinib Phosphate | 12 | $303,915 |
| TabrectaCapmatinib Hydrochloride | 13 | $299,053 |
| Lupron DepotLeuprolide Acetate | 33 | $225,047 |
| TasignaNilotinib Hcl | 12 | $200,123 |
| VenclextaVenetoclax | 12 | $164,906 |
| PromactaEltrombopag Olamine | 22 | $151,058 |
| Lenalidomide | 12 | $133,645 |
| Abiraterone Acetate | 75 | $111,549 |
| PegasysPeginterferon Alfa-2a | 13 | $53,743 |
| EliquisApixaban | 57 | $38,823 |
| OrgovyxRelugolix | 11 | $29,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $75 | $1,043,54166 claims |
| NovartisTabrecta, Tasigna, Promacta | $317 | $650,23447 claims |
| AbbVieLupron Depot, Venclexta | $45 | $389,95345 claims |
| AstraZenecaTagrisso | $49 | $348,32323 claims |
| PfizerIbrance, Eliquis | $143 | $347,12477 claims |
| Astellas Pharma US IncXtandi | $28 | $341,75137 claims |
| Incyte CorporationJakafi | $23 | $303,91512 claims |
| Johnson & JohnsonXarelto | $329 | $16,84917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Asheville
- Christopher ChayAsheville$1.5M
- Andrew BeardsleyAsheville$853K
- John PowderlyHuntersville$21.2M
- Kimberly BlackwellDurham$13.2M
- Joshua ZeidnerChapel Hill$11.2M
- Shelbi AtrashCharlotte$9.5M
- Matthew WieduwiltWinston Salem$9.5M
- Danielle BranderDurham$8.6M
- Jared WeissChapel Hill$7.3M
- Michael MorseDurham$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.